Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Table 3 Validation studies of Multinational Association for Supportive Care in Cancer score for predicting low-risk

Ref.	N episodes	Patients with hema-tological malignancy (%)	Predicted at low-risk (%)	Se (%)	Sp (%)	PPV (%)	NPV (%)
Klastersky et al[24], 2006	1003	55	72	79	56	88	40
Stratum of hematological tumors	549	100	70	77	51	84	40
Stratum of solid tumor patients	454	0	74	81	64	93	38
Uys et al[22], 2004	80	30	73	95	95	98	86
Cherif et al[23], 2006	279	100	38	59	87	85	64
Klastersky et al[24], 2006	611	43	72	78	54	88	36
Innes et al[25], 2008	100	6	90	92	40	97	20
Baskaran et al[26], 2008	116	100	71	93	67	83	85
Hui et al[27], 2011	227	20	70	81	60	86	52
Carmona-Bayonas et al[28], 20111	169	0	?	94	36	NA	NA

¹Selected patients population (“apparently” stable patients). The characteristics were calculated for a test aiming to identify low-risk patients and may then differ from the original publications. Due to the case-control design of the study, the rate of patients predicted at low risk as well as the negative and positive predictive values are meaningless. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value.